Guest guest Posted May 11, 2004 Report Share Posted May 11, 2004 Hi Alan, Find below a cut / paste from an article written by the British " National Institute for Clinical Excellence " or N.I.C.E. It is from the article regarding Product apraisal. Full article at: http://www.nice.org.uk/article.asp?a=30712 Hope it helps. Richie 4.1 Clinical effectiveness 4.1.1 No randomised controlled trials of MoM hip resurfacing arthroplasty were identified. Data were available for eight observational studies, including three studies from the manufacturers of these devices. Only four of these studies have been published. 4.1.2 Most studies reported the percentage of patients who required device revisions (MoM hip resurfacing devices to THR). However, only a few studies explicitly provided information on time to device failure, and so it is difficult to make comparisons between studies of MoM devices and THRs. Comparisons were also made difficult as few details were provided on the proportions of patients with specific preoperative diagnoses and nearly all the studies examined the outcome with more than one type of prosthesis. 4.1.3 Of the eight observational studies, the highest reported mean age at the time of surgery was 51 years, suggesting that the patients in all of these studies were relatively young compared with patients who would normally receive a THR. The mean follow-up period in seven of these studies was less than 5 years. 4.1.4 The numbers of patients included in the MoM hip resurfacing studies ranged from 4 to 4424. 4.1.5 Few data were available on dislocation rates associated with MoM devices. However, the manufacturers of the Birmingham Hip stated that the rate of dislocation for this device in the year following surgery was approximately 0.05%, based on 1 dislocation in over 1700 devices. Studies suggest that the rate of dislocation in the first year following a conventional THR may be up to 5%. 4.1.6 The proportion of patients who required device revisions (from MoM hip resurfacing to THR) was reported in all but one study and ranged between 0% and 14.3%. 4.1.7 One study relating to the use of the currently available Birmingham Hip reported 8 device failures at 4 years' follow-up. The initial cohort consisted of 1400 patients but at the time of preparing this guidance, 4 year data were available for only 21 patients. Including evidence on revision rates from the previous version of this device increased the follow-up period from 4 years to 7 years. Although only one device failure was reported over this time, the 7 year study contained fewer patients (500) than the 4 year study as the analysis was restricted to patients aged less than 55 years rather than all patients who had received the Birmingham Hip. At the time this guidance was prepared, 6 and 7 year data for this analysis were available for 40 and 20 patients respectively. 4.1.8 No other survival statistics for MoM devices were available. However, information from studies including the Swedish registry data suggests that rates of conventional THR survival in people aged less than 55 years are between 92% and 94% at 7 years. 4.1.9 Few complications were reported in any of the published studies. Little information was available on functional outcomes following MoM resurfacing and no data were available on the outcome of revisions from MoM devices to primary THRs. 4.1.10 The Assessment Group was asked to include in its review a number of alternatives to conventional THR and MoM hip resurfacing arthroplasty, including 'watchful waiting'. However, the latter option was only relevant to the extent that, if MoM devices offer (or are believed to offer) lower revision rates in younger, active patients, or better results after revision, patients and clinicians may be inclined to refer individuals for earlier consideration of hip surgery, effectively reducing the threshold for intervention. > A note from a curious (and... some would say... suspiciously twisted) > mind: Is it possible that resurfacing is 100% successful with ideal > outcomes at all times? I ask because I don't think I've read > anything since I joined the group that suggests anybody's resurf has > failed, or that it wasn't what they were told -- or hoped -- it would > be. It seems at times a little like Lake Woebegone, where all the > children are above average. > > Possible I suppose that " the others " , the unsuccessful or unhappy > ones just went away. Does Dave the rep know something he's > not telling? > > Just Idly Curious... > Alan Quote Link to comment Share on other sites More sharing options...
Guest guest Posted May 11, 2004 Report Share Posted May 11, 2004 Hi Alan, Find below a cut / paste from an article written by the British " National Institute for Clinical Excellence " or N.I.C.E. It is from the article regarding Product apraisal. Full article at: http://www.nice.org.uk/article.asp?a=30712 Hope it helps. Richie 4.1 Clinical effectiveness 4.1.1 No randomised controlled trials of MoM hip resurfacing arthroplasty were identified. Data were available for eight observational studies, including three studies from the manufacturers of these devices. Only four of these studies have been published. 4.1.2 Most studies reported the percentage of patients who required device revisions (MoM hip resurfacing devices to THR). However, only a few studies explicitly provided information on time to device failure, and so it is difficult to make comparisons between studies of MoM devices and THRs. Comparisons were also made difficult as few details were provided on the proportions of patients with specific preoperative diagnoses and nearly all the studies examined the outcome with more than one type of prosthesis. 4.1.3 Of the eight observational studies, the highest reported mean age at the time of surgery was 51 years, suggesting that the patients in all of these studies were relatively young compared with patients who would normally receive a THR. The mean follow-up period in seven of these studies was less than 5 years. 4.1.4 The numbers of patients included in the MoM hip resurfacing studies ranged from 4 to 4424. 4.1.5 Few data were available on dislocation rates associated with MoM devices. However, the manufacturers of the Birmingham Hip stated that the rate of dislocation for this device in the year following surgery was approximately 0.05%, based on 1 dislocation in over 1700 devices. Studies suggest that the rate of dislocation in the first year following a conventional THR may be up to 5%. 4.1.6 The proportion of patients who required device revisions (from MoM hip resurfacing to THR) was reported in all but one study and ranged between 0% and 14.3%. 4.1.7 One study relating to the use of the currently available Birmingham Hip reported 8 device failures at 4 years' follow-up. The initial cohort consisted of 1400 patients but at the time of preparing this guidance, 4 year data were available for only 21 patients. Including evidence on revision rates from the previous version of this device increased the follow-up period from 4 years to 7 years. Although only one device failure was reported over this time, the 7 year study contained fewer patients (500) than the 4 year study as the analysis was restricted to patients aged less than 55 years rather than all patients who had received the Birmingham Hip. At the time this guidance was prepared, 6 and 7 year data for this analysis were available for 40 and 20 patients respectively. 4.1.8 No other survival statistics for MoM devices were available. However, information from studies including the Swedish registry data suggests that rates of conventional THR survival in people aged less than 55 years are between 92% and 94% at 7 years. 4.1.9 Few complications were reported in any of the published studies. Little information was available on functional outcomes following MoM resurfacing and no data were available on the outcome of revisions from MoM devices to primary THRs. 4.1.10 The Assessment Group was asked to include in its review a number of alternatives to conventional THR and MoM hip resurfacing arthroplasty, including 'watchful waiting'. However, the latter option was only relevant to the extent that, if MoM devices offer (or are believed to offer) lower revision rates in younger, active patients, or better results after revision, patients and clinicians may be inclined to refer individuals for earlier consideration of hip surgery, effectively reducing the threshold for intervention. > A note from a curious (and... some would say... suspiciously twisted) > mind: Is it possible that resurfacing is 100% successful with ideal > outcomes at all times? I ask because I don't think I've read > anything since I joined the group that suggests anybody's resurf has > failed, or that it wasn't what they were told -- or hoped -- it would > be. It seems at times a little like Lake Woebegone, where all the > children are above average. > > Possible I suppose that " the others " , the unsuccessful or unhappy > ones just went away. Does Dave the rep know something he's > not telling? > > Just Idly Curious... > Alan Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.